Senate Report Doubts TrumpRx Amid Drug Price Hikes

A new report from Senate Democrats has cast doubt on the effectiveness of the Trump administration's TrumpRx prescription drug platform, revealing that major pharmaceutical companies raised list prices on hundreds of medications and introduced new treatments at steep costs despite entering voluntary pricing agreements with the government.

Released Thursday by Sen. Bernie Sanders of Vermont, the ranking member on the Senate Health, Education, Labor and Pensions Committee, the report analyzed pricing data and corporate filings from companies that participated in the initiative. It found that firms increased costs on more than 800 brand-name drugs in early 2026, with a median hike of about 4 percent. These adjustments affected treatments for cancer, chronic conditions, autoimmune disorders and multiple sclerosis. The companies also launched new medications, primarily cancer drugs and gene therapies, at an average annual list price of $353,000. Specific examples included Johnson & Johnson's Inlexzo at about $1 million, AbbVie's Emrelis at $719,000 and AstraZeneca's Datroway at $419,000. Novartis's one-time gene therapy Itvisma carried a list price of $2.59 million, while its...